Free Newsletter
DaVinci: Stem cell treatment helped spinal cord patients
Following up on eight acute and chronic spinal cord injury patients who were injected with bone marrow stem cells two years ago, researchers say that the therapy proved safe and effective in improving their quality of life.
DaVinci Biosciences undertook the study in Ecuador and have now issued a follow-up report claiming that MRIs have revealed "noticeable morphological changes within the spinal cord after administration of autologous bone marrow derived stem cells." There was no tumor formation, increased pain or deterioration of function following administration of the stem cell treatment.
"The outcome of this study is exciting for us and our patients; we plan on expanding and building upon the results," said Francisco Silva, president of DaVinci Biosciences. "We strongly believe that this an important first step for realizing the therapeutic application of stem cells for treating diseases and injuries such as spinal cord injury in humans."
"Although there have been numerous studies in animals demonstrating the benefits of stem cell treatment for the treatment of spinal cord injury, this is the first published study of its kind, it gives patients the possibility that their quality of life can be improved," said Dr. Paul Sanberg, Director of the Center of Excellence for Aging and Brain Repair at the University of South Florida.
- reaad the report from Medical News Today
Comments
This is a safety trial without randomization to a control therapy and without the patients and observers being blinded to the intervention. Thus, any claim about an increase in quality of life, from disabled people who agreed to the procedure in the hope for better quality of life, needs to be taken with great skepticism. QOL has many dimensions and perceived increases do not imply any functional improvement. No morphological changes in the spinal cord of experimental animals or patients have been correlated with the activity of a cellular intervention, so remain skeptical about this small study.
The 2 year follow up showed no adverse effects from treatment, regained some sensitivity and mobility, improvements on the ASIA scale and increased bladder function/sensitivity.
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession





SHARE
WITH: